Celldex Therapeutics (CLDX) Long-Term Investments (2016)

Celldex Therapeutics' (CLDX) quarterly Long-Term Investments came in at $1.8 million in Q4 2016.

Celldex Therapeutics (CLDX) Long-Term Investments (2016) Analysis & Trends

Celldex Therapeutics' Long-Term Investments history runs 1 years deep, the most recent figure standing at $1.8 million for Q4 2016.

On a quarterly basis, Long-Term Investments changed N/A year-over-year to $1.8 million in Q4 2016; TTM through Dec 2016 was $1.8 million, a N/A change from a year earlier, with the FY2016 full-year figure at $1.8 million, changed N/A from the prior year.
Long-Term Investments steadied at $1.8 million in Q4 2016 per CLDX's latest filing.
Across five years, Long-Term Investments topped out at $1.8 million in Q4 2016 and bottomed at $1.8 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	505,194.89
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	5.75 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.79 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Celldex Therapeutics	1.72 Mn	1.72 Mn	-1.44 Mn	-

Download Data

Date	Value
Dec 31, 2016	1.80 Mn